Assembly committee approves bill restricting biosimilar substitutions

08/23/2013 | California Healthline · Drug Store News

A bill that would require pharmacists to inform prescribers when they substitute a biosimilar drug for a biologic medication was approved by a California Assembly committee. The bill, SB 598, also would prevent the substitution of biosimilars when prescriptions include a "do not substitute" direction.

View Full Article in:

California Healthline · Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ